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Alzheimer’s disease (AD) is pathologically characterised by the age-dependent deposition of b-amyloid (Ab) in senile plaques,
intraneuronal accumulation of tau as neuroﬁbrillary tangles, synaptic dysfunction and neuronal death. Neuroinﬂammation,
typiﬁed by the accumulation of activated microglia and reactive astrocytes, is believed to modulate the development and/or
progression of AD. We have used primary rat neuronal, astrocytic and mixed cortical cultures to investigate the contribution of
astrocyte-mediated inﬂammatory responses during Ab-induced neuronal loss. We report that the presence of small numbers of
astrocytes exacerbate Ab-induced neuronal death, caspase-3 activation and the production of caspase-3-cleaved tau.
Furthermore, we show that astrocytes are essential for the Ab-induced tau phosphorylation observed in primary neurons. The
release of soluble inﬂammatory factor(s) from astrocytes accompanies these events, and inhibition of astrocyte activation with
the anti-inﬂammatory agent, minocycline, reduces astrocytic inﬂammatory responses and the associated neuronal loss.
Ab-induced increases in caspase-3 activation and the production of caspase-3-truncated tau species in neurons were
reduced when the astrocytic response was attenuated with minocycline. Taken together, these results show that astrocytes are
important mediators of the neurotoxic events downstream of elevated Ab in models of AD, and suggest that mechanisms
underlying pro-inﬂammatory cytokine release might be an important target for therapy.
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Alzheimer’s disease (AD) is a neurodegenerative disorder
pathologically characterised by deposits of b-amyloid (Ab)i n
senile plaques, intracellular neuroﬁbrillary tangles comprising
hyperphosphorylated tau, synaptic dysfunction and neuronal
death, some or all of which are believed to cause the cognitive
and behavioural deﬁcits that typify this disease. It is now
widely recognised that neuroinﬂammation is a prominent
feature of AD brain, with inﬂammatory responses playing a
signiﬁcant role in modulating disease progression.
1
Prolonged and widespread activation of microglia and
astrocytes are apparent in AD brain, in which the severity of
glial activation correlates with the extent of brain atrophy
2 and
cognitive decline.
3 The majority of transgenic rodent models
of AD also exhibit substantial reactive gliosis and accumula-
tion of activated astrocytes in affected brain regions.
4,5 These
features are often observed before the appearance of plaque
and tangle pathology,
6,7 and the degree of inﬂammatory cell
activation correlates with pathology development and neuro-
nal death in mouse models of AD.
6,8
Therole of microglia inthe development and/or progression
of AD is somewhat controversial. Phagocytosis of Ab by
microgliaisbelievedtobeaprotectivemechanism,
9atleastin
younger animals;
10 however, neuronal loss also results from
increased pro-inﬂammatory cytokine production by microglia
in models of AD.
10 In addition to the inﬂuence of microglia, an
important role of astrocytes in regulating Ab-induced neuronal
death has recently been illustrated.
11
Both astrocytes and microglia release a myriad of pro- and
anti- inﬂammatory cytokines, including interleukins (ILs),
interferons (IFNs) and tumour necrosis factors (TNFs), as
well as chemokines, a family of small pro-inﬂammatory
cytokines that includes macrophage inﬂammatory proteins
and monocyte chemoattractant proteins.
12 Receptor binding
of cytokines stimulates a variety of intracellular signalling
pathways that have been implicated in AD, including the
activation of protein kinase C, c-Jun N-terminal kinase (JNK),
p38 mitogen-activated protein kinase (p38/MAPK), PI3
kinase, extracellular signalling-related kinase (ERK), as well
as activation of caspase-1 and -3.
13,14
Caspases are closely associated with induction of the
apoptotic cascade, and activation of caspase-3 is both
necessary and sufﬁcient to trigger apoptotic cell death in
response to elevated Ab in AD.
15 In addition, Ab-induced
caspase-3 activation causes abnormal processing of the
microtubule-associated protein tau in models of AD.
16,17
Cleavage of tau by caspase-3 at Asp421 generates a
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www.nature.com/cddistruncated form that aggregates more rapidly, and to a greater
extent, than full-length tau,
18,19 and caspase-cleaved tau
fragments directly reduce neuronal viability.
16 Aberrant tau
phosphorylationinresponsetoelevatedAbalsocontributesto
tau aggregation and ﬁbrillisation in AD.
20 Putative tau kinases
that phosphorylate tau in response to Ab include cyclin-
dependent kinase-5, glycogen synthase kinase-3b, p38/
MAPK, JNK-1 and ERK,
21,22 several of which are activated
by increased production or release of cytokines.
13
We have shown previously that the neuroprotective agent,
minocycline, reduces tau phosphorylation and proteolysis in
both Ab-treated primary cortical cultures and also in htau
mice, which progressively accumulate hyperphosphorylated
aggregated tau and show signiﬁcant neuronal loss in the
cortex and hippocampus in the absence of elevated Ab.
17 In
htau mice, the impact of minocycline on tau pathology was not
associated with tau kinase inhibition,
17 but correlated with
reductions in astrocytosis and in the CNS burden of pro-
inﬂammatory factors.
6 Indeed, the cortical amounts of
individual inﬂammatory cytokines correlated strongly with
phosphorylated tau load.
6 Here, we have investigated the role
of astrocytes in Ab-induced tau phosphorylation and
cleavage, as well as determining the inﬂuence of astrocytes
in mediating Ab-induced neuronal death.
Results
Astrocytes accelerate Ab-induced neurotoxicity. We ﬁrst
compared primary cortical cultures in which neurons were
either cultured alone (neuronal cultures) or were in co-culture
with astrocytes (mixed cultures). Immunolabelling with cell-
type-speciﬁc antibodies identiﬁed constituent cells in the
cultures and revealed an absence of glia in neuronal
cultures. Mixed cultures were predominantly neuronal,
containing 4.4±0.4% astrocytes and a negligible amount of
microglia (o0.01%) after 7 days in vitro (DIV).
To determine whether or not astrocytes inﬂuence
Ab-induced neurotoxicity, mixed and neuronal cultures were
treated with 10mM soluble oligomeric Ab and lactate
dehydrogenase (LDH) release was used to measure cell
viability. Ab treatment of mixed cultures, but not neuronal
cultures, resulted in a statistically signiﬁcant increase in LDH
release at both 48 and 72h (Figures 1a and b; Po0.001). In
contrast, signiﬁcantly increased LDH release was only
observed in neuronal cultures following a 72h treatment with
Ab (Figure 1b; Po0.01). Ab treatment did not cause
increased release of LDH from cultured astrocytes
(Figure 1c), indicating that the presence of astrocytes
signiﬁcantly accelerates Ab-induced neuronal death.
Figure1 Astrocytesaccelerateb-amyloid(Ab)-inducedneurotoxicity.BarchartsshowLDHreleasefromratprimarymixed(blackbars)andneuronal(whitebars)cultures
exposedto 10mMAb for (a)4 8o r( b) 72h, with and withouta 24hpretreatmentwith 20mM minocycline(Min).(c)LDHrelease fromrat primaryastrocyteculturesexposedto
10mMA b for 72h, with and without a 24h pretreatment with 20mM Min. Values represent LDH release from cells into the medium as a percentage of total LDH, shown as
mean±S.E.M. Experiments were performed in triplicate (N¼9–15). *Po0.05; **Po0.01; ***Po0.001. (d) Representative images from mixed cortical cultures treated for
48h with Ab, labelled with a dead cell dye (red), and then ﬁxed and immunostained with an antibody against glial ﬁbrillary acidic protein (GFAP) (green). Bisbenzimide was
used to stain nuclei (blue). The red dye labels dead cells. Arrows indicate astrocytes that are unaffected by Ab. Scale bar: 50mm, N¼3
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Cell Death and DiseaseTo conﬁrm that neurons, and not astrocytes, are suscep-
tible to Ab toxicity in mixed culture, a ﬁxable dead cell staining
kitwas used in conjunctionwith immunolabelling ofastrocytes
(Figure1d).Asexpected,thismethodrevealedaproportionof
dead cells following Ab treatment. However, glial ﬁbrillary
acidic protein (GFAP)-immunoreactive astrocytes were not
labelled by the dead cell dye. Furthermore, the nuclei of
astrocytes were not fragmented or condensed, unlike many of
the surrounding neurons (Figure 2d, white arrows). In further
support of this ﬁnding, no alteration in the abundance of
astrocytes was apparent in mixed cultures following Ab
treatment (Supplementary Figure 1). These results support
those from the LDH assays and conclusively show that
in mixed cell cultures, only neurons are susceptible to
Ab-induced toxicity.
To determine if astrocytic inﬂammatory responses are
involved in the acceleration of Ab-induced neurotoxicity,
cultures were pretreated with the anti-inﬂammatory agent
minocycline. LDH release was not signiﬁcantly affected by
minocycline alone in any of the cultures. Pretreatment of
mixed, but not neuronal cultures with minocycline resulted in
reduced LDH release from cultures treated with Ab for 48 or
72h (Figures 1a and b; Po0.05 and Po0.001, respectively).
This ﬁnding suggests that minocycline may reduce
Ab-induced neuronal death by suppressing the inﬂammatory
response of astrocytes.
Ab induces morphological changes in astrocytes. Astrocytes
are highly dynamic cells that exhibit morphological changes
depending on their cellular environment.
23,24 In primary culture,
the morphology of astrocytes is considered a reliable marker of
their activation state.
25 Therefore, we next examined astrocyte
morphology in response to Ab and minocycline in mixed cultures.
Under control conditions, and following treatment with minocycline
alone, astrocytes appeared as stellate process-bearing cells
(Figures 2a and b), in line with previous reports.
24 Following
exposure to Ab, there were clear and robust alterations in
astrocyte morphology with the appearance of convoluted
processes and terminal swellings (Figure 2c, single arrows).
Such changes are believed to represent characteristics of
astrocyte activation in culture.
25,26 These alterations are not
indicative of dystrophic astrocytes as Ab-treated astrocytes do not
label with the dead cell dye (Figure 1d). Pretreatment with
minocycline before Ab prevented these Ab-induced morphological
changes in mixed cultures (Figure 2d).
In contrast, following Ab treatment, neurons displayed
condensed and fragmented neuronal nuclei (double arrows,
Figure 2c) and a disrupted tubulin cytoskeleton (Figure 2c).
These results add further support to our ﬁnding that neurons,
rather than astrocytes, are susceptible to Ab toxicity in mixed
culture. Pretreatment of mixed cultures with minocycline
before the addition of Ab reduced these markers of neuronal
death (Figure 2d).
These results suggest that astrocytes are activated in
response to Ab, which is an event closely associated with
Ab-induced neuronal death. Furthermore, minocycline-
mediated neuroprotection from Ab toxicity appears to be
associated with the inhibition of astrocyte activation.
A soluble factor secreted from astrocytes mediates
Ab-induced neuronal death. Astrocytes may mediate
neuronal responses both by direct membrane interactions
27
and by the release of factors that bind to neuronal
receptors.
11 To investigate the mechanism underlying the
astrocyte-mediated acceleration of Ab-induced neuronal
death, we treated primary cortical astrocyte-enriched
cultures with Ab for 48h, a treatment that is not toxic to
these cells (Figure 1c). Addition of conditioned medium from
Ab-treated astrocytes to cultured neurons resulted in
increased LDH release (Figure 3a). As a control, Ab was
incubated in astrocyte culture medium, in the absence of
cells, for 48h, and application of this medium to neurons did
not affect cell viability (Figure 3b). These results show that a
component of the astrocyte-conditioned medium mediates
neuronal death. ELISA measurement of Ab in conditioned
medium revealed that the amount of Ab reduced from 10 to
1.08±0.06mM after 48h incubation with primary astrocyte
cultures. As 1mMA b is insufﬁcient to induce neuronal death
in these cultures, we conclude that a soluble factor released
from astrocytes is important for Ab-induced neurotoxicity.
Figure 2 b-Amyloid (Ab) induces morphological changes in astrocytes. Representative images from mixed cortical cultures treated for 48h with (a) vehicle, (b)2 0mM
minocycline, (c)1 0mMA b or (d)1 0mMA b with a 24h pretreatment with 20mM minocycline. Cells were ﬁxed and immunostained with antibodies against glial ﬁbrillary acidic
protein (GFAP) (green), to label astrocytes, or bIII-tubulin (red), to label neurons. Bisbenzimide was used to stain nuclei (blue). Single arrows indicate astrocytic terminal
swellings, and double arrows indicate apoptotic nuclei. Scale bar: 50mm. N¼9
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Cell Death and DiseasePretreatment of astrocyte-enriched cultures with minocycline
before Ab application signiﬁcantly reduced neuronal death in
this model system (Figure 3b), suggesting that the neurotoxic
astrocyte-derived soluble factor(s) released in response to
Ab may be an inﬂammatory mediator.
Astrocytes increase Ab-induced caspase-3 activity. The
ﬁnding that astrocytes accelerate Ab-induced neuronal
toxicity led us to investigate whether caspase-3 activity was
inﬂuenced by astrocytes, as increased caspase-3 activity is
associated with Ab-induced neurotoxicity.
15–17 Furthermore,
we have shown that minocycline inhibits caspase-3
activation in both primary cortical cultures and in htau
mice,
17 the former closely associated with protection from
Ab-induced neurotoxicity. To investigate if astrocytes
inﬂuence caspase-3 activity, we analysed cell lysates from
Ab- and/or minocycline-treated mixed and neuronal cultures
on western blots (Figure 4).
Caspase-3 is activated by cleavage, generating fragments
of approximately 17 and 19kDa from the full-length (35kDa)
protein. We therefore measured caspase-3 activity using an
antibodyagainst cleaved caspase-3(Figure 4a).Treatment of
both mixed and neuronal cultures with Ab for 48h signiﬁcantly
increased the amount of cleaved caspase-3 present in cell
lysates, when compared with those from vehicle-treated cells
(Po0.001 and Po0.01, respectively). The activation of
caspase-3byAb wassigniﬁcantly enhanced in mixedcultures
when compared with neuronal cultures (Po0.05), indicating
that astrocytes exacerbate Ab-induced caspase-3 activation,
and this is likely related to the impact of astrocytes in
mediating Ab-induced neuronal death. Pretreatment of both
mixed and neuronal cultures with minocycline reduced the
Ab-induced accumulation of cleaved caspase-3 (Figure 4b;
Po0.01 and Po0.05, respectively). This suggests that while
astrocytic inﬂammatory responses may exacerbate caspase-
3 activation in response to Ab, both neurons and astrocytes
are targeted by minocycline to reduce caspase-3 activation.
Astrocytes exacerbate Ab-mediated tau truncation. The
truncation of tau by caspase-3 is believed to be an important
event during the development of tau pathology in AD, with
caspase-3-cleaved tau more prone to aggregation than full-
length tau.
18,19 Ab has previously been shown to induce the
generation of caspase-3-cleaved tau species in primary
cortical cultures,
17 an event associated with neuronal
death.
19,28
Therefore, cell lysates from mixed and neuronal cultures
were assessed for caspase-cleaved tau by western blotting
using an antibody that speciﬁcally detects tau that has been
cleaved at Asp421 (Figures 5a and b). In both types of control
cultures, small amounts of caspase-3-cleaved tau were
detected at approximately 50kDa, in line with our previous
ﬁndings.
17 Ab treatment signiﬁcantly increased the amount of
cleaved tau present in both mixed and neuronal cultures
(Figure 5b; Po0.001 and Po0.01, respectively); however,
signiﬁcantly more caspase-3-cleaved tau was apparent
following Ab treatment of mixed cultures when compared
with neuronal cultures (Po0.05). Cultured astrocytes contain
only trace amounts of tau (Figure 5c), suggesting that the tau
measured in the mixed cultured is of neuronal origin, and that
the presence of astrocytes signiﬁcantly potentiates the
generation of caspase-cleaved tau in neurons in response
to Ab (Figures 5a and b). Pretreatment of mixed, but not
neuronal, cultures with minocycline signiﬁcantly reduced the
amount of caspase-3-cleaved tau species generated in
response to Ab treatment (Po0.01), again suggesting that
astrocytic inﬂammatory responses may have a role in the
Ab-inducedcell signallingthatleadstocaspaseactivationand
tau cleavage.
Astrocytes are necessary for Ab-induced tau
phosphorylation. Truncation of tau is closely associated
Figure 3 A soluble factor secreted from astrocytes mediates b-amyloid (Ab)-
inducedneuronaldeath.Barchartsshowlactatedehydrogenase(LDH)releaseinto
culture medium from rat primary neuronal cultures exposed to (a) conditioned
medium from primary astrocyte cultures treated with 10 mMA b and/or 20 mM Min,
and (b) cell-free primary astrocyte culture medium infused with 10 mM Ab for 48 h,
with and without the addition of 20 mM minocycline (Min). Values are LDH release
from cells into medium expressed as a percentage of total LDH, shown as
mean±S.E.M. Experiments were performed in triplicate (N¼9). *Po0.05;
***Po0.001
Figure 4 Astrocytes increase b-amyloid (Ab)-induced caspase-3 activity.
Western blots of cell lysates from rat primary mixed (M) and neuronal (N) cultures.
Cultures were exposed to 10mMA b for 48h with and without pretreatment with
20mM minocycline for 24h. (a) Representative western blots probed with an
antibody against cleaved caspase-3 (17 and 19kDa). Blots were also probed with
b-actin(42kDa)as aloadingcontrol.Molecularweightmarkersare indicated(kDa).
(b) Bar chart showingthe amount of cleaved caspase-3 following standardisation to
b-actin in each sample. Data are mean±S.E.M. Experiments were performed in
triplicate (N¼12). *Po0.05; **Po0.01; ***Po0.001
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Cell Death and Diseasewith its phosphorylation,
29 and Ab-induced tau phosphoryla-
tion is widely regarded as an important event in AD.
22 To
determine if astrocytes mediate Ab-induced tau
phosphorylation in our model system, cell lysates from
Ab-treated mixed and neuronal cultures were assessed by
western blotting. Blots were probed with antibodies against
total tau, and tau phosphorylated at serine (Ser) 396/404
(PHF1) and Ser202 (CP13), sites previously shown to be
hyperphosphorylated in AD brain.
30
Ab treatment of mixed cultures increased tau phosphoryla-
tion at both Ser396/404 (Po0.01) and Ser202 (Po0.001)
(Figures 6a and b), when compared with vehicle-treated
cultures.Inadditiontofull-lengthtau,anadditionaltauspecies
of approximately 50kDa was labelled with both phosphoryla-
tion-speciﬁc tau antibodies on blots (Figure 6a). Co-labelling
of blots with antibodies against phosphorylated Ser396 on tau
and caspase-3-cleaved tau revealed that the 50kDa band
corresponds to caspase-3-truncated tau (Figure 6c). This
suggests that the generation of caspase-3-cleaved tau in
responsetoelevatedAboccurseitherbeforeorinconcertwith
tau phosphorylation, at least that found at the sites examined
here. No increase in tau phosphorylation at either of these
epitopes was observed upon Ab treatment of neuronal
cultures. This ﬁnding shows that astrocytes are necessary
for Ab-induced tau phosphorylation, at least in this model
system. Pretreatment of mixed cultures with minocycline
signiﬁcantly reduced tau phosphorylation at Ser396/404 and
Ser202 (Po0.05 for both). Thus, astrocytic inﬂammatory
responses likely have a role in Ab-induced tau phospho-
rylation.Furthermore, both astrocyte-mediatedtau phosphoryla-
tion and the generation of caspase-cleaved tau are closely
associated with Ab-induced neurotoxicity.
The increased release of inﬂammatory mediators
from astrocytes is associated with Ab-induced
neurotoxicity. We and others have previously shown that
the amounts of speciﬁc inﬂammatory cytokines correlate
strongly with pathology development in transgenic mouse
models of AD.
6,8 Therefore, the release of inﬂammatory
mediators from Ab- and minocycline-treated astrocyte-
enriched cultures was measured using cytokine arrays.
These arrays were chosen as they allow the unbiased and
simultaneous measurement of 29 rat cytokines.
Ab treatment of astrocyte-enriched cultures had a signiﬁ-
cant overall effect on the release of inﬂammatory cytokines
(Figure 3a; Po0.01), appearing to elevate the medium
amounts of the majority of cytokines studied, including
Figure 6 Astrocytes are necessary for b-amyloid (Ab)-induced tau phosphor-
ylation. Western blots of cell lysates from rat primary mixed (M) and neuronal (N)
cultures treated with 10mMA b for 48h±20mM minocycline (Min).
(a)Representativewesternblotsprobedwithantibodiesrecognisingtauphosphory-
lated at Ser396/404 (PHF1) and Ser202 (CP13), and total tau. (b) Bar chart shows
theamountoftauphosphorylatedateitherSer396/404(PHF1)orSer202(CP13)as
a proportion of total tau. (c) Representative western blots of cell lysates from
Ab-treated mixed cultures and neuronal cultures, probed with antibodies
recognising tau phosphorylated at Ser396 (green) and caspase-cleaved tau
(red). Molecular weight markers are indicated (kDa). Data are mean±S.E.M.
Experiments were performed in triplicate (N¼12). *Po0.05; **Po0.01;
***Po0.001
Figure 5 Astrocytes exacerbate b-amyloid (Ab)-induced tau truncation by
caspase-3.(a)Westernblotsofcelllysatesfromratprimarymixed(M)andneuronal
(N) cultures. Cultures were exposed to 10mMA b for 48h with and without
pretreatment with 20mM minocycline for 24h. Representative western blots probed
with an antibody against caspase-3-cleaved tau (50kDa) are shown. Blots were
alsoprobedwithb-actin(42kDa)asaloadingcontrol.Molecularweightmarkersare
indicated (kDa). (b) Bar chart showing the amount of caspase-3-cleaved tau as a
proportionofb-actinineachsample.(c)Representativewesternblotsofcelllysates
from primary neuron, astrocyte and mixed cultures, probed with antibodies against
total tau (55kDa) and b-actin (42kDa). Data are mean±S.E.M. Experiments were
performed in triplicate (N¼12). *Po0.05; **Po0.01; ***Po0.001
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Cell Death and DiseaseIL-1b, IL-6 and IFN-g, each of which has been reported to be
increased in response to Ab.
11 Moreover, additional cyto-
kines,notpreviouslyidentiﬁed,wereelevatedbyAb,including
IL-13, IL-17 and IP-10. Statistical analysis revealed that
cytokine-induced neutrophil chemoattractant (CINC) 2a/b,
IFN-g, IL-1b, IL-1ra, IL-6, IL-13, IL-17, IP-10 and monokine
induced by IFN-g (MIG) were signiﬁcantly increased in
response to Ab treatment (Figures 7a and b; Po0.05 for
all). Minocycline pretreatment had a signiﬁcant overall
inﬂuence on the Ab-induced increases in cytokine media
amounts (Figure 3a; Po0.001), with the Ab-induced in-
creases in the nine aforementioned cytokines being signiﬁ-
cantly reduced by minocycline pretreatment (Figures 7a and b;
Po0.05 for all). These ﬁndings indicate a close association
between cytokine release and the neurotoxic events that
occur downstream of Ab, and suggest that suppression of
these inﬂammatory responses may represent a valid ther-
apeutic strategy for the treatment of AD and related
neurodegenerative disorders.
Discussion
Here we have used cultured neurons and astrocytes to
show that astrocytes have an important role in neurodegen-
erative events occurring downstream of Ab. We found that
astrocytes exacerbate Ab-induced neurotoxicity, caspase-3
activation and the generation of caspase-3-cleaved tau
fragments, and are necessary for Ab-induced tau phosphor-
ylation. A soluble factor secreted from astrocytes appears
to have an important role in these processes, and we
have identiﬁed a panel of inﬂammatory mediators as
candidates whose secretion is increased in response to Ab.
Inhibiting astrocytic inﬂammatory responses with minocycline
reduced or abolished these effects of Ab, suggesting that the
soluble factor that has an important role in Ab-induced toxicity
and abnormal tau processing may be an inﬂammatory
cytokine.
Increased LDH release was observed 48h after Ab
treatment in mixed, but not neuronal cultures, suggesting that
astrocytes accelerate the neurotoxic effects of Ab. These
ﬁndings are in agreement with those of Paradisi et al.,
31 who
previously reported that Ab-treated astrocytes have deleter-
ious effects on neuronal cultures when co-cultured with
neurons.
31 In addition, we found that the morphology of
astrocytes was altered upon treatment with Ab, with astro-
cytes developing convoluted processes and terminal swel-
lings. Speciﬁc labelling of dead cells showed that these
morphological alterations are not indicative of atrophic
Figure 7 b-Amyloid (Ab) treatment increases the release of several inﬂammatory mediators from astrocytes. Astrocyte cultures were treated with 10mMA b for 48h with
and without pretreatment with 20mM minocycline(Min).Cytokine arrays wereused to detect theamounts of 29 inﬂammatory mediators in themedium of treatedcells. (a) Bar
chartshowsquantiﬁcationof mediumcytokineamountsin arbitrarydensitometry units(a.u.). (b)Bar chartshowspercentagechangein themedia amountsof those cytokines
signiﬁcantly inﬂuenced by Ab and/or minocycline as percentage change from control. Values represent mean±S.E.M., n¼3. *Po0.05 when compared with control;
#Po0.05 compared with Ab treated
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Cell Death and Diseasecells. Indeed, previous ﬁndings indicate that this altered
morphological state occurs when astrocytes enter an active,
cytokine-secreting state.
26 Furthermore, similar alterations to
astrocytic morphology have been reported in 3  Tg-AD mice
in which astrocytes located in close proximity to senile
plaques were shown to be hypertrophic, rather than atrophic
or dystrophic.
32
We found that Ab-induced neurotoxicity was associated
with increased activity of caspase-3, and that this was
exacerbated in the presence of astrocytes. Activated forms
of caspase-3 are found in AD brain,
28 and we have previously
shown that activation of caspase-3 precedes Ab-induced
neuronal death in primary cortical cultures.
17 The mechanism
underlying astrocyte-mediated increased caspase-3 activa-
tion in response to Ab might, therefore, be attributed to factors
that are secreted from astrocytes, or direct neuron–astrocyte
interactions. Previous evidence suggests that soluble factors
released by astrocytes bind to neuronal plasma membrane
receptors inducing various cell signalling pathways. For
example, when secreted from astrocytes, TNF-a binds to
neuronal Cd120a/b receptors triggering caspase activation
through death effector domains.
33
Astrocytes could potentially inﬂuence Ab-induced neuro-
toxicity through direct membrane-associated interactions, as
described previously.
27 However, by treating neurons with the
medium from Ab-treated astrocyte cultures, we established
that a soluble factor(s) secreted from astrocytes accelerates
Ab-induced neuronal toxicity. It is well recognised that the
activation of astrocytes is accompanied by increased produc-
tionof potentially neurotoxic factors, including cytokines, nitric
oxide (NO) and reactive oxygen species,
34 and Ab can induce
the production and secretion of IL-1b, NO and other
inﬂammatorycytokinesin culturedastrocytes andmicroglia.
35
Here, we took an unbiased approach to show that Ab
treatment signiﬁcantly increases the secretion of several
inﬂammatory cytokines and chemokines from primary astro-
cytes, and that minocycline-mediated protection from
Ab-induced neurotoxicity was associated with the decreased
secretion of inﬂammatory mediators from astrocytes. We
foundthattheamountsofCINC2a/b,IFN-g,IL-1b,IL-1ra, IL-6,
IL-13, IL-17, IP-10 and MIG in culture medium were
signiﬁcantly increased by Ab, and these increases were
signiﬁcantly inhibited by the anti-inﬂammatory agent, minocy-
cline. This suggests that these cytokines, in particular, may
have an important role in the neurotoxic events downstream
of Ab.
IL-17belongstothesamecytokinesubfamilyasIL-6,acting
to induce IL-6 expression in astrocytes.
13 Thus, this ﬁnding is
inagreementwiththoseofJanaetal.,
11whorecentlyreported
that astrocytes induce neuronal death by sphingomyelinase-
mediated induction of IL-1b and IL-6, together with TNFa.
Indeed, substantial evidence now indicates that IL-1b
and IL-6/IL-17 have important roles in the development and/
or progression of AD, with these cytokines found in affected
brain regions in association with plaques and tangles in
AD brain,
34 and transgenic mouse models of AD.
4,36 We
also found that increased IP-10 secretion from astrocytes
was associated with Ab-induced neurotoxicity. IP-10 is
markedly increased in reactive astrocytes in AD brains, and
astrocytes positive for IP-10 are associated with senile
plaques.
37 To our knowledge, the ﬁndings presented
here provide the ﬁrst evidence for a direct effect of Ab on
IP-10 production and thus may implicate IP-10 in AD
pathogenesis.
In addition to Ab-induced neurotoxicity, we have examined
the role of astrocytes in Ab-induced abnormal tau processing.
We found that astrocytes augment Ab-induced caspase-3
cleavage of tau, in keeping with our previous results.
17
We also describe, for the ﬁrst time, that astrocytes are
required for Ab-induced tau phosphorylation, at least in this
model system. Receptor binding of various cytokines and
chemokines leads to the activation of protein kinase C,
p38, ERK and JNK mitogen-activated protein kinases
and PI3 kinase.
13 Thus, it is possible that astrocyte-derived
cytokines bind to neuronal plasma membrane receptors,
inducing speciﬁc signalling pathways that result in the
activation of tau kinases implicated in aberrant tau phosphor-
ylation and cleavage in AD and the tauopathies. For example,
binding of secreted IL-1 to neuronal IL-1 receptors leads
to the activation of p38 MAPK and tau hyperphosphory-
lation in vivo.
38 Activation of caspase-3 also occurs down-
stream of IL-1 receptors,
39 which conceivably results in the
C-terminal cleavage of tau to generate neurotoxic tau
fragments.
18 Our results indicate that it is predominantly the
caspase-3-cleaved tau fragments that are more heavily
phosphorylated following Ab treatment of primary cortical
cultures, and thus uncovering the mechanism by which
astrocytes inﬂuence neuronal caspase-3 activity is likely to
elucidate the mechanism by which Ab increases aberrant tau
processing, at least in this model system. The mechanism
underlying the inﬂuence of astrocytes during Ab-induced tau
phosphorylation is currently under investigation in our
laboratory.
It is interesting to note, however, that individual cytokines
have been reported to have opposing effects on the
development of tau and amyloid pathology in transgenic
mouse models of AD.
40 Indeed, we have shown previously
that several of the cytokines identiﬁed here, including IL-17,
as being associated with Ab-associated neurotoxicity, nega-
tively correlated with the amount of tau phosphorylation
in htau mice.
6 Thus, further investigation is warranted into
the roles of speciﬁc inﬂammatory cytokines in models
of AD. Furthermore, it will be important to investigate the
ﬁndings presented here in intact brain in which the potential
inﬂuences of microglia–astrocyte signalling and complex
neurotransmitter interactions can be investigated in an
environment comprising approximately equivalent glia and
neurons.
In summary, the results presented here indicate that
astrocytes have an important role in mediating the effects of
Ab on cultured neurons. The inﬂuence of astrocytes in this
system is closely related to the increased secretion of various
inﬂammatory factors, including IL-1b, IL-17 and IP-10.
Although we cannot rule out the possibility that additional
astrocyte-derived soluble factors may have a role in the
effectsonneuronsreportedhere,theseresultsprovidefurther
supportfortheinvestigationofanti-inﬂammatorystrategies,or
the speciﬁc inhibition of selected inﬂammatory cytokines, as
potential therapies for the treatment of AD and related
neurodegenerative diseases.
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All materials were obtained from Sigma (Poole, Dorset, UK), unless otherwise
stated.
Primarycellcultureandcelltreatments. Primarymixedcorticalcultures
were prepared from embryonic day 18 (E18) rat embryos and cultured as described
previously.
17 To establish neuronal cultures, the proliferation of glial cells in mixed
cultures was prevented by the addition of 2mM cytosine arabinoside to three DIV
cultures for 48h. Primary astrocytes were obtained from postnatal day 2 (P2) rats
andcultured as describedpreviously.
41 At 2 daysbefore treatment,astrocytes were
re-plated into six-well dishes and subsequently maintained in serum-free medium.
Culturesweretreatedwith10mMsolubleoligomericAb1 42(CaliforniaPeptideCo.,
Napa, CA, USA) or 20mM minocycline for 24h before the addition of Ab or vehicle
(H2O). Soluble Ab1 42 was prepared according to the method described in Town
et al.,
21 which we conﬁrmed generates predominantly soluble oligomeric forms
of Ab.
Toxicity assays. Cytotoxicity was evaluated by measuring LDH in culture
mediumusingCytotox96 assaykits(Promega,Madison,WI,USA)accordingto the
manufacturer’sdirections.Aftercollectionofmedium,theremainingcellswerelysed
in 0.9% (w/v) Triton X-100, and LDH content in medium and lysed cells was
measured to determine total LDH content. Optical density was measured at 492nm
(Wallac 1420 Victor3 plate reader, Perkin-Elmer, Waltham, MA, USA). LDH release
from cells was calculated as a percentage of total LDH in each sample.
Dead cells in culture were identiﬁed by a live/dead ﬁxable cell stain (Invitrogen,
Paisley, UK) according to the manufacturer’s instructions. Following uptake of the
amine-reactive ﬂuorescent dye provided, cells were washed, ﬁxed and
immunolabelled with an antibody against GFAP, as described below.
Ab1 42 ELISA. Semiquantitative ELISAs were performed as described
previously,
42 using the 6E10 antibody (Eurogentec, Southampton, UK) to detect
Ab1 42inculturemedium.Ab1 42standardsofknownconcentrationwereplatedto
generate a standard curve from which Ab content was measured in the medium of
primary cortical cultures.
Immunocytochemistry. Cultured cells were ﬁxed in 4% (w/v)
paraformaldehyde in phosphate-buffered saline (PBS) for 5min at 371C.
Following ﬁxation, cells were permeabilised (0.3% (v/v) Triton X-100 in PBS) and
blocked with 1% (w/v) bovine serum albumin before incubation with monoclonal
antibodies against GFAP (Dako, Ely, UK) or bIII-tubulin (Cell Signaling, Beverly,
MA,USA).Cellswereincubatedwiththeappropriatespeciesofsecondaryantibody
and cell nuclei were stained with Hoescht 33342 (5mg/ml bisbenzimide in PBS).
Neurons were examined using a Zeiss Axioskop microscope (Carl Zeiss Inc.,
Welwyn Garden City, UK). For cell counts, ﬁve separate non-overlapping images
were taken using the  20 objective. Cell counts were made using the ImageJ
software (National Institutes of Health, Bethesda, MD, USA).
Preparation of neuronal lysates. After treatments, the medium was
removed and cells were washed in ice-cold PBS, followed by lysis in extra strong
lysis buffer (100mM Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS),
0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100, 75mM sodium chloride,
10mM ethylenediaminetetraacetic acid, 2mM sodium orthovanadate, 1.25mM
sodium ﬂuoride and protease inhibitor cocktail for mammalian tissues), and
centrifugation at 16000 gav for 20min at 41C. The protein concentration of
supernatants was measured using a BCA protein assay kit (Pierce Endogen,
Rockford, IL, USA) and samples were standardised to equal protein concentration
before being analysed on SDS-PAGE.
SDS-PAGE and Immunoblotting. In total, 5–20mg protein was separated
on 10 or 12% (w/v) SDS-PAGE gels and electrophoretically transferred to
nitrocellulose membrane. After blocking with 5% (w/v) non-fat dried milk for 1h,
membranes were probed with primary antibodies, followed by ﬂuorophore-coupled
secondary antibodies. Detected proteins were visualised and quantiﬁed, using an
Odyssey infrared imaging system (Li-Cor Biosciences, Cambridge, UK). The
following primary antibodies were used for western blotting. Total tau (rabbit
polyclonal;Dako);tau-C3(tautruncatedatAsp421,mouseIgG1;Millipore,Billerica,
MA, USA); tau (pSer396) (rabbit polyclonal; Invitrogen Biosource, Carlsbad, CA,
USA); cleaved caspase-3 (Asp175, rabbit IgG; Cell Signaling); and b-actin (mouse
IgG1, clone AC-15; Abcam, Cambridge, UK). The following tau antibodies were
kindlygiftedbyPeterDavies(AlbertEinsteinCollegeofMedicine,Bronx,NY,USA):
CP13 (phospho-Ser-202; mouse IgG1) and PHF-1 (phospho-Ser-396/404;
mouse IgG1).
Cytokine antibody arrays. The medium from astrocyte-enriched cultures
was collected and stored at  201C pending analysis of pro-inﬂammatory mediator
content using Rat Proteome Proﬁler antibody arrays (R&D Systems, Minneapolis,
MN,USA).Beforeanalysis,samplesofmediumwerethawedoniceandcentrifuged
at 10000 gav for 1min at 41C. Media from all experiments were processed in
parallel to enable comparisons between experiments. Cytokine and chemokine
content was measured according to the manufacturer’s instructions. Brieﬂy, array
membranes were incubated in blocking buffer for 1h at ambient temperature.
Samples of medium were mixed with a cocktail of biotinylated detection antibodies
before incubation at 41C with the array membranes. Following washing,
membranes were incubated with streptavidin–horseradish peroxidase for 30min
at ambient temperature. Immunoreactive species were visualised using enhanced
chemoluminescence. Positive and negative controls included in each membrane
allowedquantitativeanalysisbydensitometry,withresultsexpressedaspercentage
change from control cultures.
Statistics. DatawereanalysedusingeitherStudent’sunpairedt-testorone-way
analysis of variance (Graphpad Prism 5.0. Software, Graphpad Software Inc.,
LaJolla,CA,USA),followedbyBonferroni(forgrouped)andNewman–Keuls(forall
other analyses) post hoc tests. Differences were considered statistically signiﬁcant
when Po0.05.
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